BiotechTube
Evestra

Evestra

San Antonio, United States· Est.
evestra.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.5M

Overview

Evestra is a clinical-stage biotech specializing in women's health and oncology, built on two core technology platforms: innovative steroid medicinal chemistry and vaginal ring drug delivery. The company is advancing a pipeline addressing significant unmet needs in contraception, gynecological disorders, and oncology, with key assets likely in early to mid-stage development. Strategic initiatives include a partnership with the Bill & Melinda Gates Foundation for a long-acting contraceptive and an affiliated oncology startup in Poland, Evestra Onkologia, supported by European grants.

Women's HealthOncologyUrology

Technology Platform

Proprietary steroid medicinal chemistry and vaginal ring drug delivery technology, supported by in-house GMP API and drug product manufacturing.

Funding History

2
Total raised:$8.5M
Series A$8M
Grant$500K

Opportunities

Large, underserved markets in women's health (e.g., endometriosis, long-acting contraception) and oncology (e.g., ovarian cancer) present significant commercial potential.
Non-dilutive grant funding from prestigious organizations validates the technology and de-risks development.
The in-house GMP manufacturing facility provides strategic control and a potential future revenue stream.

Risk Factors

High clinical development risk inherent to all biopharmaceutical R&D.
Dependence on securing additional funding to advance its pipeline through costly clinical trials.
Intense competition in both women's health and oncology from larger, better-resourced companies.

Competitive Landscape

In women's health, Evestra competes with large pharma (e.g., Bayer, Pfizer) and specialty biotechs (e.g., Myovant, ObsEva) in contraception and gynecology. In oncology, particularly for targets like LIF, it faces competition from numerous biotechs and pharma companies exploring novel immuno-oncology and targeted pathways. Its differentiation lies in its proprietary steroid chemistry and delivery platforms.

More companies in Small Molecule Drugs →More companies in United States →